[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630595":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":18,"locations":24,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":27,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-1826","EXPERIMENTAL",null,[13],"Drug: SHR-1826",[15],{"type":16,"name":9,"description":9,"armGroupLabels":17,"otherNames":11},"DRUG",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":11,"email":23},"Yijun Jia","CONTACT","+0518-81220121","Yijun.jia@hengrui.com",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Affiliated Cancer Hospital of Shandong First Medical University","RECRUITING","Jinan","Shandong","250117","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.99722,36.66833,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":11,"phoneExt":11,"email":11},"Jinming Yu","PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100630595","phase-2-a-phase-ii-clinical-trial-of-shr-1826-for-non-small-cell-lung-cancer-100630595",false,"NCT07489716","A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Aged 18-75 years\n2. ECOG performance status score of 0 or 1;\n3. Histopathologically confirmed advanced or metastatic non-small cell lung cancer;\n4. Participants must provide archived or fresh tumor tissue;\n5. Participants must have experienced disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease;\n6. At least one measurable lesion according to RECIST v1.1 criteria;\n7. Expected survival ≥3 months;\n8. Adequate organ function;\n\nExclusion Criteria:\n\n1. Central nervous system metastasis or meningeal metastasis with clinical symptoms\n2. History of or concurrent other malignancies;\n3. Untreated spinal cord compression ;\n4. Uncontrolled tumor-related pain;\n5. Adverse events (AEs) from prior therapy not recovered to CTCAE Grade ≤1;\n6. History of interstitial lung disease;\n7. Severe cardiovascular\u002Fcerebrovascular diseases;","ALL","18 Years","75 Years",{"count":56,"type":57},90,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.",[63],"Non-Small Cell Lung Cancer","2026-05-12",{"date":66,"type":67},"2026-05-13","ACTUAL",{"date":69,"type":67},"2026-04-29",{"date":71,"type":57},"2028-12",{"name":5,"class":6},1]